942 related articles for article (PubMed ID: 17127117)
1. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
2. The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.
Zeitlin L; Rauch F; Travers R; Munns C; Glorieux FH
Bone; 2006 Jan; 38(1):13-20. PubMed ID: 16162424
[TBL] [Abstract][Full Text] [Related]
3. Intravenous pamidronate in osteogenesis imperfecta type VII.
Cheung MS; Glorieux FH; Rauch F
Calcif Tissue Int; 2009 Mar; 84(3):203-9. PubMed ID: 19137231
[TBL] [Abstract][Full Text] [Related]
4. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
[TBL] [Abstract][Full Text] [Related]
5. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
6. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
DiMeglio LA; Ford L; McClintock C; Peacock M
Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
[TBL] [Abstract][Full Text] [Related]
7. Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Rauch F; Munns CF; Land C; Cheung M; Glorieux FH
J Bone Miner Res; 2009 Jul; 24(7):1282-9. PubMed ID: 19257821
[TBL] [Abstract][Full Text] [Related]
8. Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta.
DiMeglio LA; Peacock M
J Bone Miner Res; 2006 Jan; 21(1):132-40. PubMed ID: 16355282
[TBL] [Abstract][Full Text] [Related]
9. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
10. Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
Rauch F; Plotkin H; Zeitlin L; Glorieux FH
J Bone Miner Res; 2003 Apr; 18(4):610-4. PubMed ID: 12674321
[TBL] [Abstract][Full Text] [Related]
11. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
[TBL] [Abstract][Full Text] [Related]
13. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
Cheung MS; Glorieux FH; Rauch F
J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.
Shapiro JR; Thompson CB; Wu Y; Nunes M; Gillen C
Calcif Tissue Int; 2010 Aug; 87(2):120-9. PubMed ID: 20544187
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
[TBL] [Abstract][Full Text] [Related]
16. Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
Gatti D; Antoniazzi F; Prizzi R; Braga V; Rossini M; Tatò L; Viapiana O; Adami S
J Bone Miner Res; 2005 May; 20(5):758-63. PubMed ID: 15824848
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
18. The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Shapiro JR; McCarthy EF; Rossiter K; Ernest K; Gelman R; Fedarko N; Santiago HT; Bober M
Calcif Tissue Int; 2003 Feb; 72(2):103-12. PubMed ID: 12457260
[TBL] [Abstract][Full Text] [Related]
19. Two doses of pamidronate in infants with osteogenesis imperfecta.
Senthilnathan S; Walker E; Bishop NJ
Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
[TBL] [Abstract][Full Text] [Related]
20. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
Gökşen D; Coker M; Darcan S; Köse T; Kara S
Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
